Key result
Statin use linked to ~31% lower risk of liver-related events in steatotic liver disease.
Why the study?
Better evidence is awaited regarding primary prevention with statins for older adults.
Cohort (n=125,926)
Yes
Answers are grounded in this paper and cite their sources.
Patient preference remains the guiding principle while we wait for better evidence
No takes yet. Share an insight, caveat, or question.
Ryan et al. (2018) conducted a cohort in Metabolic dysfunction-associated steatotic liver disease (MASLD) / Steatotic liver disease (SLD) (n=125,926). Statin use (≥ 365 cumulative defined daily dose [cDDD]) vs. Statin non-users (0 cDDD) was evaluated on Incident liver-related events (LREs), including primary liver cancer, liver cirrhosis, and decompensated liver cirrhosis (SHR 0.69, 95% CI 0.61-0.78, p=<0.001). Statin use (≥365 cDDD) reduced the risk of liver-related events compared to non-use in older adults with steatotic liver disease.
Synapse has enriched 10 related papers. Consider them for comparative context: